美国 · 财经报刊 · Investor's Business Daily
Argenx Slumps On Mixed Third Quarter, Surprise Vyvgart Testing Plans
Argenx stock fell early Thursday despite beating sales expectations on a surprise testing requirement for its drug, Vyvgart. The post Argenx Slumps On Mixed Third Quarter,…
在 Investor's Business Daily 阅读全文 登录后可收藏MarketNews 仅展示媒体发布的标题和摘要，全文请在出版方网站阅读。 (www.investors.com)
